NDAINJECTIONINJECTABLE
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Estradurin (polyestradiol phosphate) is an estrogen-based injectable medication approved in 1957 for hormone-related conditions. It is administered via intramuscular injection and represents a legacy estrogen product class with limited modern use. The drug works through estrogen receptor activation to provide hormonal replacement or palliative effects.
LOE Approaching
Legacy product in late-stage lifecycle with minimal growth trajectory; teams are typically small and focused on maintenance of existing patient base.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Estradurin presents limited career growth opportunities given zero linked job openings and LOE-approaching lifecycle status. Roles on this product are typically maintenance-focused and offer modest visibility within organizational hierarchies.
Brand ManagerSales Representative
Worked on ESTRADURIN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.